Research programme: NNR modulators - GlaxoSmithKline/Targacept

Drug Profile

Research programme: NNR modulators - GlaxoSmithKline/Targacept

Latest Information Update: 23 Oct 2012

Price : $50

At a glance

  • Originator Targacept
  • Class Small molecules
  • Mechanism of Action Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Drug abuse; Obesity; Pain; Parkinson's disease; Smoking withdrawal

Most Recent Events

  • 04 Mar 2011 The strategic alliance between Targacept and GlaxoSmithKline terminates, effective May 2011
  • 06 May 2008 Targacept selects a lead compound for development in smoking cessation triggering a milestone payment from GlaxoSmithKline
  • 11 Dec 2007 A lead candidate from this research programme, TC 6499, enters clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top